Business Context and Reporting Period
Company: Daxor Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
Business Overview: Daxor operates in medical services and technology, primarily through its Idant Laboratory division (semen and blood banking) and the development of the Blood Volume Analyzer (BVA-100). In 1998, the Company received FDA clearance to market the BVA-100 and began beta testing in hospitals. Operations for the Idant Laboratory were restricted throughout 1998 due to legal proceedings regarding licensing but were restored to full functioning in February 1999 following a settlement.
Key Financial Metrics
| Metric | 1998 | 1997 |
|---|---|---|
| Total Revenues | $2,629,438 | $2,813,173 |
| Operating Revenues | $324,192 | $529,737 |
| Dividend Income | $1,942,759 | $2,138,755 |
| Net Income (Loss) | $(420,460) | $(158,853) |
| Net Income Per Share | $(0.09) | $(0.03) |
| Total Assets | $44,056,349 | $41,322,592 |
| Shareholders' Equity | $35,303,834 | $32,917,724 |
| Working Capital | $34,837,930 | $32,501,404 |
| Short-Term Debt | $2,050,549 | $2,494,639 |
| Market Value of Securities Portfolio | $43,016,243 | $40,347,085 |
Note: The Company's financial position is heavily supported by a diversified securities portfolio (primarily utility stocks) which generated significant dividend income and unrealized gains, offsetting operating losses.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 6.5% to $2.63 million, driven by a 39% drop in operating revenues ($324k vs $530k) due to the suspension of Idant Laboratory operations. Dividend income also declined by roughly 9%.
- Widening Loss: Net loss increased significantly from $158,853 in 1997 to $420,460 in 1998. This was exacerbated by higher operating expenses for the laboratories ($961k vs $629k) and increased interest expenses ($485k vs $167k).
- Investment Gains: Gains on the sale of investments increased substantially to $362,487 from $144,681, partially mitigating the operating loss.
- Debt Reduction: Short-term debt decreased by approximately $444,000, reducing from $2.49 million to $2.05 million.
- Regulatory Resolution: A major non-financial change was the settlement of lawsuits with the State of New York in November 1998, resulting in the re-licensing of the semen and blood banks in February 1999.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management intends to focus marketing efforts on the Blood Volume Analyzer (BVA-100), estimating a potential market exceeding $100 million annually. The Company plans to market the BVA-100 on a sale and loaner basis to hospitals and imaging centers. Additionally, Daxor plans to develop a national network of cryo-centers for blood and sperm banking. The Company believes it is in a satisfactory financial position with adequate funds for immediate needs, though expansion may require additional capital.
Risks and Contingencies
- Regulatory Risk: Operations are subject to FDA and state health department regulations. While licenses were restored in early 1999, future compliance is critical.
- Market Acceptance: The primary hindrance to the BVA-100 is demonstrating cost-effectiveness and accuracy to the medical community.
- Competition: The medical technology market is competitive, though Daxor holds patents for the BVA-100 and its injection kit. The sperm banking sector has over 300 competitors in the U.S.
- Liquidity Dependence: The Company relies heavily on its securities portfolio for liquidity and to offset operating expenses. A significant decline in the value of this portfolio could impact financial stability.
Investor Verification Checklist
- Operational Restart: Verify that Idant Laboratory operations have fully resumed and are generating revenue post-February 1999 licensing.
- BVA-100 Commercialization: Confirm the status of beta testing results and the number of hospital contracts secured for the Blood Volume Analyzer.
- Portfolio Valuation: Assess the stability of the $43 million securities portfolio, which constitutes the majority of assets and a primary source of income.
- Debt Covenants: Review terms of the $2.05 million short-term debt secured by marketable securities to ensure no margin call risks exist.
- Related Party Receivables: Investigate the $75,979 past-due receivable from a related corporation noted in the financial statements.